Patrys Ltd

PAB

Company Profile

  • Business description

    Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

  • Contact

    Level 4, 100 Albert Road
    South Melbourne
    MelbourneVIC3205
    AUS

    T: +61 396703273

    https://www.patrys.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    23

Stocks News & Analysis

stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks

Could merger breathe new life into struggling ASX asset manager?

Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,815.305.00-0.06%
CAC 407,789.4139.88-0.51%
DAX 4024,083.55171.76-0.71%
Dow JONES (US)44,371.51279.13-0.63%
FTSE 1008,972.7631.640.35%
HKSE24,203.3263.750.26%
NASDAQ20,585.5345.14-0.22%
Nikkei 22539,459.62110.06-0.28%
NZX 50 Index12,678.697.99-0.06%
S&P 5006,259.7520.71-0.33%
S&P/ASX 2008,570.409.70-0.11%
SSE Composite Index3,519.659.470.27%

Market Movers